Pfizer inks licensing deal with Russia’s SatRx for diabetes drug

Pfizer ($PFE) has taken another step toward externalizing research and development. The U.S. drug giant sealed a licensing deal with Russian drug developer SatRx, which has garnered exclusive rights t…
Read the full story: News